Nivolumab

SUSPENDED · PHASE2 · Progressive Glioblastoma, Recurrent Glioblastoma

Scheduled Interim Monitoring

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.